SKIN & AESTHETICS / COMPARE
Two Pathways. Side by Side.
Where Melanotan II and GHK-Cu converge, where they diverge, and how far the evidence behind each one actually reaches.
The short version
This page lines up Melanotan II and GHK-Cu on the dimensions that matter when reading research peptides: what kind of molecule each is, where it has been studied, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest documented concern.
The headline is direct. Both peptides act on skin. Melanotan II acts on the pigmentation machinery via a potent receptor agonist route and has small but controlled human data — alongside an unambiguous list of documented adverse events, no regulatory approval anywhere, and an active unregulated market. GHK-Cu acts on the connective-tissue matrix via fibroblast signaling and has the most human evidence of the two — but that evidence is topical and small-scale, limited by its own skin-crossing problem. Neither is an approved medicine. Neither is presented here with a human dose.
The comparison matrix
| Dimension | Melanotan II | GHK-Cu |
|---|---|---|
| Peptide class | Cyclic heptapeptide; non-selective melanocortin agonist (MC1R-MC5R) | Copper-binding tripeptide / copper tripeptide-1 (cosmetic ingredient / research peptide) |
| Most-studied in | Skin pigmentation, erectile function, appetite regulation | Skin matrix regeneration, collagen synthesis, hair growth |
| Evidence base (model) | 2 controlled human Phase I studies (n=3; n=10) + case reports [5][6] | In vitro + small controlled human topical trials; one 45-patient combination hair-loss RCT [10][11] |
| Administration studied | Subcutaneous injection (Phase I studies) [5][6] | Topical; ex vivo skin penetration [8][12] |
| Regulatory / WADA status | Not approved anywhere; WADA S0 prohibited in sport at all times | Topical cosmetic ingredient legal (US/EU/UK); systemic unapproved |
| Key caution | Documented mole changes / melanoma reports; renal injury; priapism; unregulated supply [3] | Poor skin permeability limits topical bioavailability; pigmentation risk with some formulations [8] |
Peptide class
The two differ at the class level. Melanotan II is a cyclic heptapeptide (seven amino acids, ring-closed for stability) that acts as a non-selective agonist at all five melanocortin receptors — MC1R through MC5R. It was designed specifically to be a more potent and stable form of the endogenous alpha-MSH hormone [4]. GHK-Cu is a linear tripeptide (three amino acids) chelated to a single copper ion. Its three-residue sequence appears inside structural collagen, which points to its role: not as a receptor agonist but as a matrix-building signal [11].
Most-studied in
Each compound has a home territory. Melanotan II's research centers on pigmentation, erectile function, and — more recently in animal models — appetite and food motivation [1][2][5][6]. GHK-Cu is overwhelmingly a skin-and-matrix story: collagen, elastin, glycosaminoglycan synthesis, and the gene-level rebalancing that supports repair [9][11]. Hair growth is the one area where GHK-Cu has a controlled human trial [10]; Melanotan II's hair relevance is through MC1R-driven melanogenesis in the follicle, which has been studied as a mechanism in model systems but has no corresponding hair-growth clinical dataset.
Evidence base (model)
This is where the two genuinely separate in ways that matter for reading the claims made about them. Melanotan II has two published controlled human studies — both small Phase I work in single digits to a dozen subjects [5][6] — plus a body of case reports that are almost all adverse events: renal infarction, eruptive nevi, melanoma, priapism [3]. The adverse-event case literature is longer than the efficacy literature. GHK-Cu has more human efficacy data, mostly topical, and one 45-patient hair-loss RCT using a combination product [10][11]. Its adverse-event record is shorter and less severe, dominated by formulation-level cautions and a pigmentation risk noted in some microneedling protocols [8].
Administration studied
Routes reflect the questions asked. Both Phase I Melanotan II studies used subcutaneous injection [5][6]; Melanotan II is not water-soluble in the same sense as some peptides and is typically reconstituted for injection. GHK-Cu's human evidence is almost entirely topical: creams, serums, and in the 2025 review, experimental systems like microneedle pretreatment and palmitoylated analogs designed to improve skin crossing [8]. An ex vivo skin-penetration study quantified copper movement through dermatomed human skin — 136 micrograms/cm² permeated over 48 hours [12]. Neither has validated pharmacokinetics in humans for injectable or systemic routes.
Regulatory and WADA status
Neither is an approved medicine for any indication. Melanotan II has not reached Phase II or Phase III trials; it has no approval from the FDA, EMA, TGA, MHRA or any other regulatory body, and regulators including the US FDA, Australia's TGA and the UK's MHRA have issued specific warnings against tanning products containing melanotan. WADA lists it under S0 (Non-Approved Substances), prohibited in sport at all times [4]. GHK-Cu is unusual: topical copper tripeptide-1 is a legal and widely used cosmetic ingredient with a long market history; injectable or systemic use crosses into unapproved research-chemical territory with no established pathway [8].
Key caution
Each compound carries a defining concern. For Melanotan II it is the documented pattern of serious harm: changing and new moles, melanoma reports, renal injury, priapism, and a pervasive unregulated supply where product identity and purity are unknown [3][7]. These are not theoretical risks extrapolated from mechanism — they are in the case-report literature. For GHK-Cu the principal documented limitation is the skin-crossing problem: without delivery engineering, much of a topical dose does not reach the dermis where fibroblasts live [8]. A secondary issue is the localized pigmentation risk seen with some copper-peptide applications. Reading them together: one compound's biggest issue is a safety record; the other's is a delivery problem.